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Intact ParathyroidHormone:Performanceand ClinicalUtilityof an AutomatedAssay
Based on High-PerformanceImmunoaffinityChromatographyand
ChemiluminescenceDetection
David S. Hage,’ Bob Taylor,2

and Pal C. Kao2

The performance
and clinical utility of an automated
assay of intact parathyroid hormone (parathyrin, PTH) are
evaluated. The method is based on the extraction of PTH
from plasma by an HPLC column containing immobilized
anti-(44-68 PTH) antibodies. The PTH retained is detected with a postcolumn reactor and use of anti-(1--34
PTh) chemiluminescent-labeled antibodies. The total cycle time of the assay is 6.5 mm per injection after a 1-h
incubation. The lower limit of detection for PTH in a 66-pL
plasma sample was 0.5 pmol/L based on peak heights
and 0.2 pmol/L based on peak areas. Mean analytical
recovery for PTH added to plasma was 97%. The withinday precisions (CVs) for 4.2 and 30 pmol/L PTH plasma
samples were 9.2% and 5.6% and the day-to-day precisions were 10.3% and 5.7%, respectively. No significant
interferences from 1-34,44-68,
or 53-84 PTH fragments
were noted, even at highly increased concentrations of
fragments. The correlation of results with those of a
manual assay of intact PTH was 0.97, and the results
showed good agreement with disease state for patients
with hypo- or hyperparathyroidism. The specificity of the
assay for primary hyperparathyroldism was >95%. We
discuss the advantages (speed and quality control) of this
approach over current immunoassays and the potential
use of this method for detecting other analytes.
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The measurement
of parathyrin
(parathyroid hormone; PTH), an 84-amino-acid peptide produced by the
parathyroid
glands, is a useful tool in the diagnosis of
calcium disorders.3
The main function of PTH is to
control the concentration of calcium in extracellular
fluids, with the excretion of PTH increasing as the
calcium concentrations decrease (1,2). Normal concentrations of intact PTH in plasma range from -1 to 5
pmol/L, with both the increased and decreased values
being of clinical interest (2, 3). Besides intact PTH,
various
fragments
representing
the N-terminal,
midmolecule, and C-terminal
regions of PTH are also found
in blood. Most of these fragments
are formed afte
release of intact PTH into the circulation, but some
also produced within the parathyroid
glands (4). Bo
intact PTH and its N-terminal
fragment are biologicall
active, with intact PTH being the predominant
activ
form under normal conditions
(2).
PTH assays are used clinically
in the differenti
diagnosis
of disorders that produce
hypercalcemia
o
hypocalcemia
(e.g., primary hyperparathyroidism
or hy
percalcemia
of malignancy)
and in monitoring
hon
damage in patients with chronic renal failure (1,2). Th
pathology
and clinical importance
of these disorde
have been previously discussed (1-6).
Numerous
methods are available for the clinical mea
surement of PTH in these disorders. These are typicall
based on immunoassays
with antibodies directed tow
the N-terminal,
midmolecule,
or C-terminal regions o
FFH. One factor complicating
the use and comparison o
these
assays
is that they have different
degrees
o
responseto intact PTH and its circulating
fragments
(1
2). Several methods for monitoring only intact
were recently reported, based on two-site immunometri
assays (7-9). In these assays two sets of antibodies
used: one set is immobilized
onto a solid support an
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used to bind one end of intact PTH, such as its 1-34
N-terminal region; the second set is labeled and used to
identify the presence of PTH by binding to a second
domain, such as the 44-68 midmolecule region. Given
this combination, only intact FF11 will react with both
sets of antibodies and be detected (7-9).
Routine monitoring of intact PTH is best done with a
method that is not only sensitive but also fast and fully
automatable. However, current intact PTH assays are
manual methods that take a long time to perform (i.e.,
typically 24 h). To overcome these problems, we (10)
recently developed an automated
system for intact PTH,
based on high-performance
immunoaffinity
chromatography and chemiluminescence
detection
(HPIAC/CL).
En this method, PT!! plasma samples are first incubated
with acridinium
ester-labeled anti-(1-34 PT!!) antibodies. This mixture
is then injected onto a column
containing anti-(44-68 F1’H) antibodies immobilized to
a small-particle,
silica-based
support. The immobilized
antibodies extract from the sample any intact PTH
present, along with its associated
labeled antibodies.
After nonretained
components and excess labeled antibodies are washed from the column, a low pH buffer is
applied to elute intact P’FH and its associated labeled
antibodies from the column. As these compounds are
eluted, they are combined on-line with an alkaline
peroxide postcolumn reagent; the resulting production
rf light from the acridinium
ester label is measured
with a flow-through detector. The column is then regenerated, and the next sample is injected (10).
In a previous report we described
the design and
eptimization of this system for PT!! determinations
10). Here we examined the performance
and utility of
this method in a routine clinical setting we considered
the response, precision, and accuracy of the method and
the effects of potential interferences, such as circulating
PT!! fragments.
We also examined how this method
rrelated
with manual PTH immunoassays
and cornared the results of this technique
for patients with
ypo- and hyperparathyroidism
with those obtained for
ormal individuals.
The potential advantages
and lim-

tations of this method in the automation of immunoasys of PT!! and other compounds are discussed.
aterlals and Methods
eagents
The 1-34, 1-44, 44-68, and 56-84 fragments of huPT!! and 1-84 intact human FF11 were obtained
m Peninsula Labs. (Belmont, CA). The cyanogen
romide-activated
Sepharose
4B, goat IgG, and bovine
rum albumin
(BSA; RIA grade) were from Sigma
hemical Co. (St. Louis, MO). Triton X-100, electrophois grade, was from Fisher Scientific (Fair Lawn, NJ).
-(2-Succinimidyloxycarbonylethyl)-phenyl-10-methylcridinium-9-carboxylate
fluorosulfonate
(i.e., acridinester) was from London Diagnostics
(Eden Prairie,
- The Nucleosil
Si-1000 (7-pin particle
diameter,
00-nm pore size) was obtained from Alltech Associates
eerfleld, IL). The 0.25-in. (6.3-mm) polymeric beads
in the immunochemiluminornetric
assay (ICMA)

were from Micrornembranes,
Inc. (Newark, NJ). All
solutions were prepared with water from a Milli-Q
Water System (Millipore, Bedford, MA).
Instrumentation
The chrornatographic
system was the same as dobefore (10). We used a Hitachi (Tokyo, Japan)
L-6200 ternary pump for mixing and pumping postcolumn reagent
and two Hitachi L-6000 isocratic pumps
for delivering the application and elution buffers to the
immunoaffiaity
column. Samples were injected with a
Hitachi 655A-40 autosampler. Components leaving the
immunoafflnity
column in the elution buffer were dotected on-line with an 825-CL chemiluminescence
detector (Jasco, Easton, MD). The application and elution
buffers were applied alternately to the immunoaffinity
column through a column-switching
system consisting
of a Rheodyne 5701 tandem enrichment
valve and a Vici
DVI actuator (Chromtech,
Apple Valley, MN), controlled from the L-6200 pump. The data were collected
and processed by a Hitachi D-2500 Chrornatolntegrator.
scribed

Procedures
Anti-(1-34 PTH) antiserum was prepared in goats by
using BSA-conjugated
1-44 PT!! as the initial immunogen, followed by later injections of unconjugated 1-44
FF1!. Before use, these antibodies were affinity-purified
in columns containing
1-34 FFH fragments immobilized onto a 7 mm (i.d.) x 15 cm cyanogen bromideactivated
Sepharose
4B column (10).
Anti-(44--68
FFH) antiserum was prepared by injecting goats with BSA-conjugated
44-68 Fr!!. The anti(44-68 P’FH) antibodies
were also affinity-purified,
with
use of 44-68 PTH fragments immobilized onto a 7 mm
(i.d.) x 15 cm cyanogen bromide-activated
Sepharose
4B
column (10).
The anti-(1-34
FF11) antibodies
were labeled with
acridimum
ester and purified on a 7 mm (i.d.) x 15 cm
1-44 PTH cyanogen bromide-activated
Sepharose
4B
affinity column
as described
previously (11). Active
labeled antibodies
collected from the affinity column
were diluted in 0.10 mol/L phosphate buffer, pH 7.4,
containing
1 g of BSA, 1 g of goat IgG, and 1 mL of
Triton X-100 per liter, then stored at -20 #{176}C
until
required for further use.
The manual ICMA assay used in the correlation
studies was performed as described previously (9). The
acridinium

ester-labeled

anti-(1-34

PT!!)

antibodies

were the same as used with the HPIAC/CL system. The
beads bearing immobilized
antibody
were prepared
by
attaching
the affinity-purified
anti-(44-68
FF1!) antibodies to the polymeric beads, according
to the manufacturer’s instructions.
At the end of the assay, we
measured the chemiluminescence of the beads by using
a Magic Lite Analyzer (Ciba Corning,
Medfleld, MA).
Chromatography
The immunoaffinity
column
was prepared as doscribed previously (10), by using affinity-purified
anti(44-68 PT!!) antibodies
immobilized
onto diol-bonded
CLINICALCHEMISTRY,Vol.38, No.8, 1992 1495

Nucleosil Si-1000 silica. Using the bicinchoninic acid
protein assay (12), we estimated that 1.4mg of antibodies per gram of silica was immobilized onto the support.
The anti-(44-68
PTH) Nucleosil support was downward slurry-packed
at 25 MPa into 4.0 mm (i.d.) x 2.0
cm stainless steel columns from Upchurch (Oak Harbor,
WA). Samples were injected onto the column in 0.10
mol/L potassium
phosphate buffer, pH 7.4, containing 1
mL of Triton X-100 and 1 g of BSA per liter. The
retained
PTH was eluted with pH 3.0 potassium phosphate buffer (0.10 mol/L), containing Triton X-100, 1
mL/L. All chromatography
was performed at room temperature.

were prepared by adding 1-84 human
plasma collected from patients
with hypoparathyroidism
and having no endogenous
FF1! production. For analysis, we mixed 200 pL of each
plasma sample with 100 pL of a 50-fold dilution of the
acridinium
ester-labeled antibodies in phosphate buffer
(0.10 mol/L, pH 7.4) containing 1 mL of Triton X-100, 1
g of BSA, and 1 g of goat IgG per liter. The samples were
then filtered through 0.45-pm pore size ACRO LC13
disposable filters (Gelman Sciences, Ann Arbor, MI) and
incubated in the autosampler tray of the HPLC at room
temperature
for at least 1 h. We then injected 100 pL of
sample onto the HPIAC/CL
system at a flow rate of 1.0
mLlmin. We used the following event schedule in each
chromatographic
analysis: 0.0 mm, switch column to pH
7.4 phosphate buffer and allow column to regenerate;
1.0 mm, inject sample and wash nonretained
components and excess labeled antibody from the column; 3.0
mm, switch to pH 3.0 phosphate elution buffer and
detect the FF11 and associated labeled antibodies;
6.5
mm, begin next cycle.
Retained PT!! and associated
labeled antibodies were
detected as they eluted from the column by combining
the column eluent with a postcolumn
reagent containing, per liter, 10 mL of Triton X-100, 0.75 mol of sodium
hydroxide,
and 0.43 mmol of hydrogen peroxide. This
reagent was prepared
on-line, as described previously
(10), and was applied to the system at a flow-rate of 1.0
mL/min. The post-column
reagent and column eluent
were combined by using a standard
miring tee from
Upchurch. The mixture was then immediately passed
through the flow cell of the on-line chemilumineacence
detector, and the light produced by the acridinium ester
label was monitored.
FF1! standards

PT!! to EDTA-treated

Subjects
were obtained by collecting
plasma from 45 healthy volunteers between ages 20 and 60 y. These volunteers were laboratory technicians
and individuals
participating
in a
study to determine normal values. All normal subjects
had total serum calcium concentrations between 2.13
and 2.50 mmol/L (mean 2.29 mmolJL).
EDTA-treated
plasma
samples
were also obtained
from 46 patients with surgically confirmed
primary
hyperparathyroidism.
These samples were collected before removal of the affected parathyroid
glands. The
Normal

FF11 samples

EDTA-treated
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mean total serum calcium in these patients was 2.8#{128}
mmol/L (range 2.50-3.23). The mean serum creatininc
and inorganic phosphorus concentrations in these pa.
tients were 85 pmol/L (range 44-230) and 0.89 mmol/I
(range 0.58-1.26), respectively.
EDTA-treated
plasma samples were collected from 40
patients with chronic renal failure. Their mean tots.]
serum calcium concentration
was 2.41 mmol/L (range
1.48-2.90), mean serum creatinine
was 710 pmoI/L
(210-1200),
and mean inorganic
phosphorus was 2.2?
mmol/L (range
EDTA-treated

1.07-5.78).

plasma samples were obtained from 3
individuals with hypercalcemia
of malignancy.
The following types of malignancies
were represented: squamous cell carcinoma (n = 8), lymphoma (n = 6), breast
cancer (n = 4), renal cell carcinoma (n = 4), multiple
myeloma (n = 4), prostate cancer (n = 2), sarcoidosis (ii
= 2), and 1 each of small cell carcinoma,
islet cell
carcinoma,

lung adenocarcinoma,

hemangiopericytoma,

dysgermmnoma, ovarian tumor, paraganglioma,
and
grade 4 adenocarcinoma
with an unknown
primary
origin. The mean total serum calcium in these patients
was 3.23 mmol/L (range 2.83-3.95). Their mean serum
creatinine
and inorganic
phosphorus
concentrations
were 130 pmol/L (range 60-410) and 1.01 mmol/L
(range 0.58-1.58),
respectively.
Results
Assay Performance
The carryover of the HPIAC/CL system was <0.16%,
as determined by mi’king several alternate injections of
1000 and 0 pmoliL FFH plasma standards.
On the basis
of these carryover studies and previous work, we developed the event schedule given in Materials and Meth.
ods. With this scheme, the total chromatographic
tim
was only 6.5 mm per injection, following a 1-h incuba
tion of sample with labeled antibody. Earlier studie
have shown that most (>70%) of the PTH and label
antibodies
bind within this incubation
time (10); co
quently, even samples
that are incubated for >1
before injection present only slight variations in th
final signal produced with this system.
Under the above chromatographic
conditions, th
minimum
turnaround
time per sample was -1 h, in
cluding the time required for sample preparation, incu
bation, injection,
and analysis. Given a chroma
graphic time of 6.5 mm per sample, the theoreti
throughput
of this system is 220 samples per day.
practice, an average calculated throughput of 180 ± 2
samples
per day (n = 19 days) has actually been o
tamed.
Typical chromatograms
obtained with the HPIAC/C
system are shown in reference 10. An example
of
calibration curve generated
with this system is sho
in Figure 1. These results were obtained by injecting
single set of plasma standards
onto the system. T
quantify the amount of FFH represented
by each
one can use either peak heights or areas. Based o
multiple injections of low-concentration PTH stan
the lower limit of detection at a signal-to-noise ratio of

Table 2. ParallelIsm of Intact PTH Results on the

HPIAC/CL System
Pm conan, pmoVL
DIlutlon

Undiluted

PTH conc, pmol/L
beet-fit line to the first six data points Inthegraph: y = (0.040 ± 0.0O1)x
(0.167 ± 0.011). The inse,t shows an expanded view of the graph Inthe
region of the four lowest concentration standards
- -,

Coed
for dilution

101.0

101.0

1:2

49.4

98.8

1:4

24.6

1:8
1:16

12.7
6.41

98.4
102.0
102.6

Undiluted

Fig. 1. TypIcal calibration curve for PTH on the HPIAC/CLsystem
basedon peak-height measurements

Measured

39.2

1:2
1:4
1:8

19.1
10.6
4.74

1:16

2.51

a Twopatients’ samples were dilutedwith a 0 pmo[/L PTH

39.2
38.2
42.4
37.6
40.2

plasma

standard.

+

Table 1. AnalytIcal Recovery of Intact PTH on the
HPIAC/CL System
pm concn, L
Erdogsneu.
2.5
2.5
2.5

3.4
3.4
3.4

Added
3.1
7.3
19.9
3.7

PScov.r.da
5.5
9.5
20.8
6.7

6.8
10.5

10.4
13.6

R.covsiy, S
98
97
93
94

102
98

Results shown are for single sample Injections.

was determined as 0.2 pmol/L for peak-area
measurements and 0.5 pmol/L for peak-height measurements.
These limits of detection reflect the concentration of
injected FF1! required to produce a signal 2 SD above
the signal produced by the zero standard and agree with
previous data obtained with this system (10).
As shown in Figure 1, the linear range (i.e., the range
of concentrations
within
± 5% of the best-fit
line)
extended up to 38 pmol/L for the peak-height
measurements. For peak-area
measurements,
the same standards demonstrated
a linear range extending
to 44
pmol/L. Thus, the peak-height
and peak-area
calibration curves had linear ranges for concentrations covering 1.8 and 2.3 orders of magnitude, respectively. These
results also agree with earlier work on this system (10)
and are similar to linear ranges seen for manual PTH
assays. The dynamic range (i.e., the range of concentrations producing any detectable change, linear or nonlinear, in the response) extended up to at least 250 pmol/L,
with no apparent hook effect.
Analytical recovery of intact PTH in the HPIAC/CL
system was determined by analyzing
normal plasma
samples supplemented
with various amounts of exogenous intact PTH. As Table 1 illustrates,
all samples
showed a high degree of recovery, with values ranging
from 93% to 102% (mean 97%).

Parallelism of the HPIAC/CL
system was assessed by
measuring
intact PTH in a series of dilutions prepared
from plasma samples with above-normal
concentrations
of FF1!. The data for all diluted samples showed excellent agreement
with the results predicted
from the
original sample (Table 2). For the first sample, the
average relative error was only -0.6% (range -2.6% to

+ 1.6%); for the other sample, the average relative error
was +1.0% (range -4.1% to +8.2%).
The within-day precision of the automated FF1! assay
was measured by making 20 sequential
injections
of
plasma samples with either normal or abnormal concentrations of FF1! (4.2 and 30 pmolJL, respectively).
The
within-day
precisions
(CVs) for these samples were ±
9.2% and ± 5.6%, respectively. The day-to-day precision
of the system was determined by injecting the same
samples over the course of 10 d. The day-to-day precision was ± 10.3% for the normal samples and ± 5.7% for
the abnormal samples. All of these results are similar to
those obtained with equivalent manual FFH immunemetric assays (7, 8).
The immobilized
antibody
solid-phase
used in this
work was stable for several months when stored at 4#{176}C
in pH 7.0 phosphate
buffer. When the support was
placed in a column, typical column lifetimes of 200-250
plasma injections were obtained (mean 230, SD 30, for
three columns). This column life is similar to that seen
for other antibodies
immobilized
to silica (13-16) and
indicates
that the system was sufficiently stable for
performing
many analyses of patients’ samples.
As shown previously, little or no change in the activity of the immobilized
antibody
was found under the
elution conditions used in the HPIAC/CL system (10).
Measuring
the total binding capacity of the immobilized
antibody support over multiple elution cycles had shown
that the total binding capacity of the column for 44-68
FFH decreased
by <0.3% with each elution cycle (10).
In this study, we further examined column stability by
comparing a series of five calibration curves obtained
over a series of 143 injections with use of a single
column and a single labeled-antibody preparation. AlCLINICALCHEMISTRY,Vol.38, No.8, 1992 1497
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Ag. 2. Correlationof HPIAC/CLwith a manual intact PTH immunechemlluminometrlcassay (ICMA). Best fit line:y = (0.99 ± 0.04)x +
(0.7 ± 0.6), corr. coef. = 0.97, n = 130
though some random variation was noted between the
individual calibration curves, linear regression of the
slopes and intercepts indicated
no significant change
(<6%) in the curves over the course of this study,
whether based on peak heights or peak areas. From this
we concluded that the stability of the immobilized
antibody was not a mnjor factor in limiting the column
life.
One important
factor affecting column life was a
buildup in pressure after a large number of plasma
samples were injected. To reduce this pressure increase,
we implemented several precautions
throughout
this
study, such as filtering all samples before injection and
placing a precolumn
filter in the system to prevent
particulate
matter from reaching the immobilized-antibody column. Changes in the pressure of the system
during the application and elution steps were also
monitored
for quality control. Pressure monitoring
was
useful because it indicated when and where pressure
was increasing
and what type of corrective action was
needed. Typical sources of pressure
increases
were the
precolumn
ifiter and column. To minimize these increases in routine testing,
we replaced the frit in the
precolumn
filter after every 100 injections and changed
the column after every 200 injections.
To determine
the correlation of the HPIAC/CL system
with a manual intact PTH assay, we used both procedures to analyze
a series of 130 patients’ samples in
which intact FF1! concentrations ranged from 0.5 to 42
pmol/L. The best-fit line between the results of the two
assays (Figure 2) had a slope (±2 SD) of 0.99 ± 0.04 and
an intercept of 0.70 ± 0.6 pmol’L; the correlation coefficient was 0.97.
Clinical Utilityand InterferenceStudies
Figure
3 shows the results
obtained
with the
HPJ.AC/CL system for single determinations of normal
plasma samples and samples obtained
from patients
with primary hyperparathyroidism,
chronic renal failure, or hypercalcemia
of malignancy. For the 45 normal
samples tested, the mean concentration of intact PTH
was 2.2 pmol/L; the total range of concentrations observed was 0.6-5.6 pmol/L. Using nonparametric
anal1498 CLINICAL CHEMISTRY, Vol. 38, No.8, 1992
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I

I

Normals

KM

I

1 HPT

CRF

Fig.3. Plasma concentrations of intact PTh measured by HPIAC/CL
In normal individuals and in patients with hypercalcernia of malignancy (HM), primary hyperparathyroidlsm (1 #{176}HPT),
or chronic renal

failure(CRF)

ysis and a range of ± 2 SD from the mean, we determined the normal range for intact FF1! by this method
to be 0.9-5.3 pmol/L. This is consistent with normal
ranges reported for manual intact FF11 assays (3, 7,8).
For the 46 patients tested with primary hyperparathyroidism,
FFH concentrations
ranged from 5.1 to 41.1
pmol/L (mean 14.6 pmol/L). Results for all samples but
one were above the normal range. This gave the
HPIAC/CL
method a specificity for primary hyperparathyroidism of >95%; thus, this technique easily discriminates between normal individuals
and patients with
primary

hyperparathyroidism.

FFH results for patients with chronic renal failure are
also shown in Figure 3. As reported by others, samples
from these patients exhibit a wide range of PTH concentrations (9). In our hands, these concentrations ranged
from 3.5 to 90.0 pmol/L, or from normal values up to
extremely
high concentrations.
For patients with hypercalcemia
of malignancy,
most
samples contained either low or undetectable
concentrations of FFH (Figure 3). In more than half of the samples
tested (58%), the measured
FFH concentrations were
below the lower limit of detection of the system (<0.2
pmol/L). P’FH values measured
in the rems%ining patients ranged from 0.3 to 1.7 pmol/L. Those samples
with
results within the normal
range included two
patients with metastatic
breast cancer and one with
metastatic renal cell carcinoma. Considering all of the
malignancy
samples tested, 92% were at or below the
lower limit of the normal range (0.9 pmol/L) and all
were below the mean of the normal range (2.2 pmol/L).
There was no overlap between the FF1! concentrations
in the patients with hypercalcemia
of malignancy
and
in those with primary hyperparathyroidism.
To test for potential interferences, we added 1-34,
44-68, or 53-84 FF1! to plasma samples containing 0 or
5 pmol of FFH per liter and injected these onto the
HPIAC/CL
system.
The concentration of FF1! fragments added to the samples ranged from 0 to 35 nmol/L.

In these studies, we noted no detectable

interference in
either the 0 or 5 pmol/L FF1! samples at concentrations
as great as 30 nmol/L for 53-84 PTH or 20 nmolJL for
44-68 FFH. No interference from 1-34 FF1! was seen
for a fragment concentration as great as 250 pmolfL.
These quantities of fragments
exceed the concentrations
seen in most clinical situations, including chronic renal
failure, and indicate that little interference
would be
expected from these fragments
in routine testing. The
1-34 P’TH results also suggest that this assay would
have little or no interference
from PTH-related peptide,
which has its greatest structural
homology with FF1! in
the 1-13 N-terminal
region (17).
DIscussion
This study demonstrates
that HPIAC/CL
is a useful
approach to the routine analysis of intact FF1!. Not only
is the method fully automatable, but it also has precisions, limits of detection, and results comparable with
those of current PTH assays. This development is important because no fully automated method for FF1! has
previously been reported.
One key advantage of this method is that its overall
analysis time (i.e., 1 h per sample) is significantly
shorter than that reported for comparable manual PTH
assays. For example, Nussbaum
et al. (8) reported a
24-h immunoradiometric assay for quantifying intact
FF1! in 200 L of serum; its limit of detection was -0.1
pmol/L. Brown et al. (9) reported a 5-h manual ICMA
for 100-zL samples, with a limit of detection of 0.8
pmol/L.
One reason for the greater speed of this method is the
much larger excess of antibody used in the HPIAC/CL
system than is typically present in a manual immunoassay support. This allows for more rapid binding between
the immobilized antibody and the FF11-labeled-antibody complex. The support used in the HPIAC/CL system is also much smaller than that used in manual
immunoassays; this results in faster mass transfer and
also provides for more rapid extraction of the FFHlabeled-antibody complex. In previous studies (10), we
showed that the combination of these two factors produced a net rate of extraction of FF1! and its associated
labeled antibody 2400-fold faster than that for the
same sample and antibodies used with a standard
immunoassay bead.
This HPIAC/CL
method is not limited to FF1! but can
be adapted to detect other compoundsby using different
labeled antibodies and columns. Such an approach
should be particularly
useful in analyzing
other lowconcentration peptide hormones for which automated
systems are not available (e.g., calcitonin and corticotropin). We are also examining the use of HPIAC/CL
to
determine smaller molecules.
One potential advantage of HPIAC/CL
over existing
methods for P’FH is that it analyzes samples sequentially
rather than in a batch mode. This should make
HPIAC/CL
potentially
easier for troubleshooting
and
maintaining
quality control. For example, if the result
for a control sample is outside its allowed limits with

it is relatively easy to change the column or
buffers and recheck the control without wasting a substantial amount of time before patients’ samples are
tested. In contrast, the long analysis times of manual
FF1! methods means that controls and samples must
be analyzed simultaneously. This creates a problem if the
results for the controls are later found to be outside
acceptable limits, because diagnosing
and fixing the
problem may take several days. This increases time and
cost because the patients’ samples must be redetermined.
The fast analysis times of HPIAC/CL make it attractive to use for rapid determinations
of individual samples or for small-scale routine analysis. For situations
requiring
throughput of several hundred samples per
day, either multiple HPIAC/CL
systems or batch-mode
manual immunoassays
are recommended.
HPIAC/CL,

is an attractive alternative
for determining
intact FF1! in
plasma. This method has the advantages of being both
fast and fully automatable, while retaining the accuracy, precision, and response of manual P’FH assays. In
addition, HPIAC/CL has the potential of being more
cost-effective and of maintaining quality control more
easily than present batch assays. All of these characteristics make this approach appealing for use in the
routine monitoring of intact FF1! and other low-concentration analytes.
In summary,

to manual

1!PIAC/CL

methods
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